WO2007119279A1 - コイヘルペスウイルス(khv)病用dnaワクチン - Google Patents
コイヘルペスウイルス(khv)病用dnaワクチン Download PDFInfo
- Publication number
- WO2007119279A1 WO2007119279A1 PCT/JP2007/051498 JP2007051498W WO2007119279A1 WO 2007119279 A1 WO2007119279 A1 WO 2007119279A1 JP 2007051498 W JP2007051498 W JP 2007051498W WO 2007119279 A1 WO2007119279 A1 WO 2007119279A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- khv
- protein
- seq
- amino acid
- dna
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Definitions
- KHV Koi herpesvirus
- the present invention relates to a DNA vaccine for inducing protective immunity against Koi herpesvirus (KHV) infection in fish.
- KHV Koi herpesvirus
- Koi herpesvirus disease is a disease that occurs in maggots and shikigoi due to infection with koi herpesvirus (KHV), and when it develops, its ability to slow down and stop eating External symptoms include faint discoloration and erosion (sagging), which occurs from juveniles to adults, and is a disease with a high mortality rate.
- KHV koi herpesvirus
- Vaccines are generally used for the prevention or treatment of viral infections.
- inactive vaccines Japanese encephalitis, Weil disease, etc.
- toxoids toxoids
- attenuated vaccines BCG, polio, etc.
- genetically modified vaccines hepatitis B virus, etc.
- Inactive vaccines and toxoids detoxified with exotoxins are relatively safe vaccines that induce antibodies against them.
- Genetically modified vaccines are considered safer because they do not contain impurities when compared to inactivated vaccines.
- Vibrio disease inactive vaccine In addition, currently approved as a marine vaccine in Japan, Vibrio disease inactive vaccine, ⁇ -hemolytic streptococcal disease inactive vaccine, iridovirus infection inactive vaccine, j8 hemolysis Sexual streptococcal inactive vaccine only.
- DNA vaccine a new vaccine species that induces immunity
- the disadvantages of type vaccines have been improved.
- DNA vaccines can induce not only humoral immune responses but also cellular immunity, so that they can provide protection against infections and can be highly purified.
- it is stable at room temperature or high temperature, refrigerated storage is not essential, it can be stored for a long time, it is easy to improve DNA vaccines quickly by genetic engineering techniques, and it is spent on vaccine development There are advantages such as time reduction.
- Patent Document 1 Japanese Patent Laid-Open No. 9 176043
- Patent Document 2 JP-A-2005-112726
- Patent Document 3 Japanese Patent Laid-Open No. 2002-125674
- Patent Document 4 Japanese Patent Laid-Open No. 9-285291
- Non-Patent Document 1 P. Boudinot et.al, Virology, (USA), 1998, Vol.249, p.297-306
- Non-patent Document 2 McLauchlan et.al, Fish and Shellfish Immunology, England, 2003, Vol.
- An object of the present invention is to provide a carp DNA vaccine for inducing protective immunity against koi herpesvirus (KHV) disease.
- the present inventors have intensively studied to develop an effective vaccine against koi herpesvirus (KHV) disease, and have developed all of koi herpesvirus (KHV) gene DNA in Japan, the United States, Israel, and Indonesia.
- the base sequence was determined, and from among the approximately 180 genes, five genes encoding glycoherpesvirus (KHV) glycoproteins and five genes encoding membrane proteins were selected.
- KHV glycoherpesvirus glycoproteins
- membrane proteins encoding membrane proteins
- the present invention provides (1) (a) glycoprotein of koi herpesvirus (KHV) comprising the amino acid sequence shown in SEQ ID NO: 2, 4, 6, 8 or 10, (b) SEQ ID NO: 2, In the amino acid sequence shown in 4, 6, 8, or 10, one or several amino acids are deleted, substituted or appended, and the immunogenicity against koi herpesvirus (KHV).
- KHV glycoprotein of koi herpesvirus
- KHV koi herpesvirus
- Koi herpesvirus (KHV) membrane protein (e) from the amino acid sequence shown in SEQ ID NO: 12, 14, 16, 18 or 20, wherein one or several amino acids are deleted, substituted or added A protein having immunogenicity against koi herpesvirus (KHV), or (f) an amino acid sequence having at least 80% homology with the amino acid sequence shown in SEQ ID NO: 12, 14, 16, 18 or 20 And a DNA encoding a protein having immunogenicity against koi herpesvirus (KHV).
- the present invention also relates to (6) DNA having the nucleotide sequence shown in SEQ ID NO: 11, 13, 15, 17 or 19 or a complementary sequence thereof, and (7) SEQ ID NO: 11, 13, 15, 17 or 19 DNA encoding a protein having a nucleotide sequence in which one or several bases are deleted, substituted or added, and having immunogenicity against koi herpesvirus (KHV), (8) It hybridizes with DNA with stringency complementary to the nucleotide sequence shown in SEQ ID NO: 11, 13, 15, 17 or 19 under stringent conditions and has immunogenicity against koi herpesvirus (KHV) DNA encoding the protein, (9) glycoprotein of koi herpesvirus (KHV) consisting of the amino acid sequence shown in SEQ ID NO: 2, 4, 6, 8 or 10, and (10) SEQ ID NO: 2, 4, 6 , 8 or 10, in the amino acid sequence 1 Or a protein having an amino acid sequence in which several amino acids are deleted, substituted or added, and having immunogenicity against k
- the present invention provides (13) a recombinant vector comprising one or more DNAs selected from among the DNAs described in any one of (1) to (8) above, (14) the above ( The key force of the DNA described in any one of 1) to (8) is also selected.
- the DNA vaccine for caries containing 1 or 2 or more DNAs (15) The DNA vaccine for caries containing the recombinant vector of (13) above, (16) A method for preventing or treating koi herpesvirus (KHV) disease, comprising administering to the carp the DNA vaccine for carp described in (14) or (15) above, (17) Use of the carp DNA vaccine described in 14) or (15) to induce an immune response against carp herpesvirus (KHV) disease, or (18) any of (9) to (12) above An antibody characterized by specifically recognizing the protein of (19) and a gene expression vector of the protein according to any one of (9) to (12) above. It can be obtained by introducing about trans di We nick Koi compound having a resistance to Le Bae scan virus (KHV) to Koi, wherein.
- KHV koi herpesvirus
- FIG. 1 is a diagram showing the results of a DNA vaccine test for KHV infection.
- A Test results when each of the 5 types of glycoprotein genes is administered
- B Test results when each of the 3 types of membrane protein genes is administered
- FIG. 2 is a diagram showing the results of a test using a DNA combination vaccine for KHV infection.
- the vertical axis represents cumulative mortality and the horizontal axis the number of days after KHV infection.
- Groupl is a negative control test group.
- Group2 is a membrane protein test group.
- Group3 is a glycoprotein test group.
- the DNA of the present invention includes (a) DNA encoding a koi herpesvirus (KHV) glycoprotein consisting of the amino acid sequence represented by SEQ ID NO: 2, 4, 6, 8 or 10, and (b ) In the amino acid sequence shown in SEQ ID NO: 2, 4, 6, 8 or 10, consisting of an amino acid sequence in which one or several amino acids are deleted, substituted or added, and immunity against koi herpesvirus (KHV) DNA encoding a protein having an originality, (c) SEQ ID NO: 2, 4, DNA encoding a protein comprising an amino acid sequence having at least 80% homology with the amino acid sequence shown in 6, 8 or 10 and having immunogenicity against koi herpesvirus (KHV), or SEQ ID NO: 1 1 or several bases in the base sequence shown in SEQ ID NO: 1, 3, 5, 7 or 9 or in the base sequence shown in SEQ ID NO: 1, 3, 5, 7 or 9 DNA that encodes a protein having an immunogenicity against the parenthesus herpes
- KHV koi herpesvirus
- DNA consisting of a base sequence and encoding a protein having immunogenicity against koi herpesvirus (KHV), or DNA having a complementary sequence to the base sequence shown in SEQ ID NO: 11, 13, 15, 17 or 19 DNA that encodes a protein that hybridizes under stringent conditions and has immunogenicity against koi herpesvirus (KHV) is not particularly limited, and the protein of the present invention includes SEQ ID NO: In the amino acid sequence shown in 2, 4, 6, 8 or 10, the powerful koi herpesvirus (KHV) glycoprotein or the amino acid sequence shown in SEQ ID NO: 2, 4, 6, 8 or 10 A protein having an amino acid sequence deleted, substituted or added, and having immunogenicity against koi herpesvirus (KHV), SEQ ID NO: 12, Amino acid sequence shown in 14, 16, 18 or 20 In the koi herpesvirus (KHV) membrane protein consisting of a row or the amino acid sequence shown in SEQ ID NO: 12, 14, 16, 1 8 or 20, one or several amino
- the protein is not particularly limited as long as the protein has an amino acid sequence and has immunogenicity against koi herpesvirus (KHV).
- a protein having immunogenicity against koi herpesvirus (KHV) refers to a protein capable of stimulating and inducing an immune response (including humoral immunity and cellular immunity) against koi herpesvirus (KHV) when in vivo.
- amino acid sequence in which one or several amino acids are deleted, substituted or added is, for example, 1 to 20, preferably 1 to 15, more preferably 1 to: LO, and further preferably Means an amino acid sequence in which any number of 1 to 5 amino acids have been deleted, substituted or added.
- base sequence in which one or several bases are deleted, substituted or added is, for example, 1 to 20, preferably 1 to 15, more preferably 1 to: LO, and still more preferably. It means a base sequence in which any number of 1 to 5 bases is deleted, substituted or added.
- DNA consisting of a base sequence in which one or several bases are deleted, substituted or added is known to those skilled in the art such as chemical synthesis, genetic engineering techniques, mutagenesis, etc. It can also be produced by any method. Specifically, mutations are made to DNA consisting of the base sequence shown in SEQ ID NO: 1, 3, 5, 7, or 9 or DNA containing the base sequence shown in SEQ ID NO: 11, 13, 15, 17 or 19 Mutant DNA can be obtained by introducing a mutation into these DNAs using a method of contacting with the original drug, a method of irradiating with ultraviolet rays, a genetic engineering technique, or the like.
- Site-directed mutagenesis which is one of genetic engineering techniques, is a technique that can introduce a specific mutation at a specific position.
- Molecular Cloning A Laboratory Mannual, 3rd Ed., Cold bpnng Ha rbor Laboratory, Cold Spring Harbor, NY., 2001. (hereinafter abbreviated as "Molecular Cloning 3rd Edition"), Current Protocols in Molecular Biology, Supplement 1-38, John Wile y & Sons (1987-1997)
- Molecular Cloning 3rd Edition Current Protocols in Molecular Biology, Supplement 1-38, John Wile y & Sons (1987-1997)
- base sequence that hybridizes under stringent conditions refers to DNA or RN A base sequence obtained by using a nucleic acid such as A as a probe and using the colony hybridization method, plaque hybridization method, Southern blot hybridization method, etc. Specifically, using a filter in which DNA derived from colonies or plaques or a fragment of the DNA is immobilized, in the presence of 0.7 to 1.0 M Na C1, the hybridization is performed at 65 ° C. After washing, the filter is washed at 65 ° C using 0.1 to 2 times the SSC solution (1x concentration of SSC solution is 150 mM sodium chloride and 15 mM sodium citrate). Can identify the DNA that can be identified. Hybridization can be performed according to the method described in Molecular Cloning 3rd edition and the like.
- the stringent condition refers to a condition in which a so-called specific hybrid is formed and non-specific hybrids and hybrids are not formed. Specifically, a homology of 50 to 70% or more is required.
- the condition is that the DNAs that have DNA hybridize and the DNAs with lower homology do not hybridize with each other are the conditions for normal Southern hybridization washing at 65 ° C, IX SSC, 0.1 0/0 SDS, also ⁇ or 0. IX SSC, 0. 1 0/ 0 SDS into the threaded eyes those to Roh in salt concentration, can be mentioned Iburidizu conditions.
- DNA that can be hybridized under stringent conditions includes DNA having a certain degree of homology with the base sequence of the DNA used as a probe, for example, 60% or more, preferably 70%.
- a DNA having a homology of at least%, more preferably at least 80%, further preferably at least 90%, particularly preferably at least 95%, most preferably at least 98% can be suitably exemplified.
- the method for obtaining and preparing the DNA of the present invention is not particularly limited.
- ⁇ MA, 11, 13, 15, 17 or ⁇ MA19 [Indicated base sequence information, SEQ ID NO: 2, 4, 6, 8 or 10, or SEQ ID NO: 12, 14, 16, 18 or 20
- appropriate probes and primers are prepared and used to screen the koi herpesvirus (KHV) DN ⁇ library to identify the gene of interest.
- KHV koi herpesvirus
- the method for obtaining and preparing the protein of the present invention is not particularly limited. However, it may be a chemically synthesized protein or a recombinant protein produced by gene recombination technology.
- the protein of the present invention can be obtained by appropriately combining the methods for isolating and purifying the protein, such as cells or tissue that express the strong protein.
- a protein is prepared by chemical synthesis, for example, according to a chemical synthesis method such as Fmoc method (fluorenylmethyloxycarbonyl method), tBoc method (t-ptyloxycarbonyl method), etc. Proteins can be synthesized.
- the protein of the present invention can be synthesized using various commercially available peptide synthesizers.
- the protein of the present invention can be prepared by introducing DNA consisting of a base sequence encoding the protein into a suitable expression system.
- preparation by gene recombination technology that can be prepared in a large amount by a relatively easy operation is preferable.
- the protein of the present invention is prepared by gene recombination technology
- ammonium sulfate or ethanol precipitation in order to recover and purify the protein from the cell culture, ammonium sulfate or ethanol precipitation, acid extraction, key-on
- a known method including cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxyapatite chromatography and lectin chromatography, preferably high performance liquid chromatography is used.
- the column used for the affinity chromatography is, for example, a column in which an antibody such as a monoclonal antibody against the protein of the present invention is bound, or a normal peptide tag added to the protein of the present invention.
- purified products of these proteins can be obtained.
- a purified sample can be obtained by performing the above-described purification treatment after allowing the cell membrane degrading enzyme to act.
- amino acids are deleted, substituted, or added in the amino acid sequence shown in SEQ ID NO: 2, 4, 6, 8, or 10, or SEQ ID NO: 12, 14, 16, 18, or 20.
- a protein having an amino acid sequence ability or a protein consisting of an amino acid sequence having 80% or more homology with the amino acid sequence shown in SEQ ID NO: 2 is SEQ ID NO: 2, 4, 6, 8, or Is SEQ ID NO: 1, 3, 5, 7 or 9, or SEQ ID NO: 11, which shows an example of the base sequence encoding the amino acid sequence shown in SEQ ID NO: 12, 14, 16, 18 or 20, respectively.
- Those skilled in the art can appropriately prepare or obtain the information based on the nucleotide sequence information shown in 13, 15, 17 or 19.
- the recombinant vector of the present invention is a set capable of expressing a protein having the gene DNA of the present invention and having immunogenicity against a coil herpesvirus (KHV) in a carp in vivo.
- the recombinant vector is not particularly limited as long as it is a replacement vector, and the recombinant vector of the present invention can be constructed by appropriately integrating the gene DNA of the present invention into an expression vector.
- the expression vector is preferably one that can replicate autonomously in the host cell, or one that can be integrated into the host cell's chromosome. Those containing the first order control sequences can be preferably used.
- an expression vector for animal cells particularly a recombinant vector using an expression vector for fish cells is preferable.
- the procedure and method for constructing an expression vector that can be used in the present invention are in the field of genetic engineering. It can be used conventionally.
- Examples of the control sequence that can be used in the present invention include a constitutive promoter, an inducible or regulatory promoter, a tissue-specific promoter, or a promoter derived from the gene of the expressed antigen. It is not particularly limited as long as it can be expressed in the cells.
- Constitutive promoters include, for example, cytomegalovirus (CMV) derived promoter sequences, or Rous sarcoma virus (RSV), simian virus-40 (SV-40), muscle 13 actin promoter, or simple herpes. Examples include strong promoters such as viruses (HSV).
- Examples of the tissue-specific promoter include a thymidine kinase promoter.
- inducible or regulatable promoters include growth hormone regulatable promoters, promoters under the control of the lac operon sequence, and dumbbell inducible metamouthoneone promoter.
- the transcriptional regulatory sequence can be operably linked to a nucleotide sequence encoding an immunogenic polypeptide (ie, so that expression of the nucleotide sequence can be regulated).
- the control sequence may include an expression control sequence including a promoter (eg, the inducible or constitutive promoter) DNA sequence, and if desired, further enhancer element, transcription or polyadenylation signal.
- a promoter eg, the inducible or constitutive promoter
- the expression vector may be a bacterial replication origin sequence, or an antibiotic resistance (eg, kanamycin) gene or a non-antibiotic resistance gene (eg, a j8-galatatosidase gene), if desired. ) And other selectable markers.
- an antibiotic resistance eg, kanamycin
- a non-antibiotic resistance gene eg, a j8-galatatosidase gene
- the carp DNA vaccine of the present invention includes a composition containing one or more selected DNAs of the DNA of the present invention and a composition containing the above-described recombinant vector of the present invention.
- a composition containing one or more selected DNAs of the DNA of the present invention and a composition containing the above-described recombinant vector of the present invention.
- it is not particularly limited, it consists of a cocktail of 5 kinds of DNA consisting of the base sequences shown in SEQ ID NOs: 1, 3, 5, 7 and 9 and a base sequence shown in SEQ ID NOs: 11, 13, 15, 17 and 19.
- a cocktail of 5 types of DNA, a cocktail of these 10 types of DNA, and a recombinant vector capable of expressing these DNA cocktails are preferred.
- an adjuvant can be added to the DNA vaccine for core of the present invention.
- Adjuvants stimulate the immune system and enhance the immune response to antigens, and are mainly added to vaccines as adjuvants.
- a typical adjuvant for example, an aluminum compound, a polynucleotide, or a force known to have a bacterial cell component, such as Coi IL 1 j8 zebra IFN-a, etc. can be suitably exemplified.
- a plasmid into which IL-1 ⁇ gene or IFN- ⁇ gene is inserted so that it can be expressed in the body can be prepared and inoculated into fish together with the vaccine of the present invention.
- KHV koi herpesvirus
- the fish to which the carp DNA vaccine of the present invention can be applied is not particularly limited as long as it is a fish that can be infected by koi herpesvirus (KHV). Name Nishikigoi It can be done.
- antibodies that specifically bind to the protein of the present invention include monoclonal antibodies, polyclonal antibodies, chimeric antibodies, single chain antibodies, humanized antibodies and the like. These are the powers that can be prepared by conventional methods using the above-mentioned glycoproteins and membrane proteins as antigens. Among them, monoclonal antibodies are more preferable in terms of their specificity.
- An antibody that specifically binds to the protein of the present invention, such as a strong monoclonal antibody, is useful for, for example, separation and quantification of the protein of the present invention and to elucidate the molecular mechanism of the protein of the present invention.
- the antibody against the protein of the present invention can be obtained by administering a fragment containing the protein or epitope or a cell expressing the protein on the membrane surface to an animal (preferably a non-human) using a conventional protocol.
- an animal preferably a non-human
- the preparation of monoclonal antibodies may result in antibodies produced by continuous cell line cultures, such as the hypridoma method (Nature 256, 495-497, 1975), the trioma method, the human B cell hyperpridoma. Any method can be used such as the method (Immunology Today 4, 72, 1983) and the EBV-hybridoma method (Monoclonal Antibodies and Cancer The rapy, pp. 77-96, Alan R. Liss, Inc., 1985).
- the antibodies such as the monoclonal antibody of the present invention include, for example, fluorescent substances such as FITC (fluorescein isocyanate) or tetramethylrhodamine isocyanate, 125 i, 32 P, 14 C, 35 S or 3 H
- fluorescent substances such as FITC (fluorescein isocyanate) or tetramethylrhodamine isocyanate, 125 i, 32 P, 14 C, 35 S or 3 H
- FITC fluorescein isocyanate
- tetramethylrhodamine isocyanate tetramethylrhodamine isocyanate
- a protein labeled with an enzyme such as alkaline phosphatase, peroxidase, / 3-galatatosidase or phycoerythrin
- a fusion protein fused with a fluorescent protein such as green fluorescent protein (GFP)
- GFP green fluorescent protein
- transgenes that are resistant to the koi herpesvirus of the present invention include transgenes obtained by gene transfer of one or more gene expression vectors of the protein of the present invention. If it is a carp, it is not particularly limited.
- a promoter that efficiently expresses the protein gene of the present invention in carp cells Connected downstream of It is preferable to produce an expression vector.
- Such promoters include: 13-actin Promo ⁇ ⁇ "Ta ' ⁇ ", aaipocyteP2 aP2) Flomo ⁇ Ta' ⁇ , Mylz2 (Danio reno myosin light polypeptide 2 skeletalmuscle mylz2) promoter, UCP promoter, SV40 promoter, site Mega viral promoter, EF1 alpha promoter, meta port Chio Ne Inn promoter primary, and power among them medaka ⁇ - Akuchinpu port motor can be exemplified heat shock promoter, my l z 2 promoter is preferable in terms of expression efficiency.
- a polyaformati silkworm sequence such as a ushi growth hormone polyadulylated sequence downstream of the protein gene of the present invention.
- an intron sequence an enzyme sequence having a function of enhancing gene expression, or a terminator sequence for instructing transcription termination may be used.
- the constructed expression vector can be introduced into the carp by a microinjection method into an oocyte or a fertilized egg, a viral vector infection method, a particle gun method, or an elect mouth position method.
- the transgenic caries of the present invention include, for convenience, carp fertilized egg cells, carp embryo cells, and the like, in addition to carp adults and progeny into which the protein gene of the present invention has been introduced.
- HV-g4-R SEQ ID NO: 28 5 '-TCAGAGTTCGTCTCTGATG G-3'
- KHV-ml F SEQ ID NO: 31 5'-ATGACGGAGCGGGCAGCGCT-3 '
- the PCR amplified DNA was cloned into the gene expression vector pcDNA3.1 and introduced into E. coli.
- the transformed Escherichia coli was cultured in large quantities, and plasmid DNA was extracted and purified. Purification of the plasmid was performed by ultracentrifugation using molecular salt cesium (Molecular Cloning 3rd edition) o
- a vaccine test was conducted in the same manner as described above. At this time, 5 types of glycoprotein genes (group2) and 5 types of membrane protein genes (group3) were mixed and inoculated. As a negative control, vector plasmid DNA alone (groupl) was inoculated. For 30 days after vaccination, breeding was carried out in a circulating filtration tank at 23 ° C, and infection experiments were conducted as described above.o
- the carp DNA vaccine of the present invention can confer immunity against carp herpes virus disease caused by koi herpes virus (KHV). More specifically, according to the DNA vaccine for koi of the present invention, an immune response (including a humoral immune response and a cellular immune response) against koi herpesvirus disease can be induced. It is effective in preventing the infection of Luz (KHV) or treating Koi herpesvirus disease.
- KHV koi herpes virus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2007800128639A CN101495636B (zh) | 2006-04-13 | 2007-01-30 | 锦鲤疱疹病毒(khv)病用dna疫苗 |
US12/296,459 US8052977B2 (en) | 2006-04-13 | 2007-01-30 | DNA vaccine for Koi herpes virus (KHV) disease |
EP07707716.2A EP2011876B1 (en) | 2006-04-13 | 2007-01-30 | Dna vaccine for koi herpes virus (khv) disease |
JP2008510736A JP5239023B2 (ja) | 2006-04-13 | 2007-01-30 | コイヘルペスウイルス(khv)病用dnaワクチン |
TW096114531A TW200842189A (en) | 2006-04-13 | 2007-04-24 | DNA vaccine for Koi herpes virus (KHV) disease |
IL194474A IL194474A0 (en) | 2006-04-13 | 2008-10-02 | Dna vaccine for koi herpes virus (khv)disease |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006-111414 | 2006-04-13 | ||
JP2006111414 | 2006-04-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2007119279A1 true WO2007119279A1 (ja) | 2007-10-25 |
Family
ID=38609100
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2007/051498 WO2007119279A1 (ja) | 2006-04-13 | 2007-01-30 | コイヘルペスウイルス(khv)病用dnaワクチン |
Country Status (7)
Country | Link |
---|---|
US (1) | US8052977B2 (ja) |
EP (1) | EP2011876B1 (ja) |
JP (1) | JP5239023B2 (ja) |
CN (1) | CN101495636B (ja) |
IL (1) | IL194474A0 (ja) |
TW (1) | TW200842189A (ja) |
WO (1) | WO2007119279A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010109874A1 (ja) | 2009-03-26 | 2010-09-30 | 国立大学法人東京海洋大学 | コイヘルペスウイルス特異的抗体及びその抗原 |
JP2015503914A (ja) * | 2011-12-30 | 2015-02-05 | ユニヴェルシト ド リエージュ | Khvにより引き起こされる疾患の防止のための組換えコイヘルペスウイルス(khv)およびワクチン |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2796178C (en) | 2010-04-21 | 2021-02-16 | Pharmaq As | Nucleic acid sequences of fish cardiomyopathy syndrome virus and the use thereof |
EP2487241A1 (en) | 2011-02-09 | 2012-08-15 | Westfälische Wilhelms-Universität Münster | RNAi agents and compositions useful as carp therapeutics |
CN104736169B (zh) * | 2012-09-10 | 2018-04-17 | 国立大学法人东京海洋大学 | 海产鱼的类结节病用dna疫苗 |
CN102988973A (zh) * | 2012-10-29 | 2013-03-27 | 吉林农业大学 | 一种锦鲤疱疹病毒核酸疫苗 |
CN102973951A (zh) * | 2012-11-26 | 2013-03-20 | 吉林农业大学 | 一种锦鲤疱疹病毒orf25核酸疫苗 |
EP2950816B1 (en) | 2013-02-04 | 2019-07-31 | Schweitzer Biotech Company Ltd. | The use of dna sequences encoding an interferon as vaccine adjuvants |
GB2551984B (en) | 2016-06-30 | 2019-01-16 | Pharmaq As | Fish virus |
CN111635961B (zh) * | 2020-06-30 | 2024-05-10 | 广东省农业科学院动物卫生研究所 | 锦鲤疱疹病毒检测试剂盒和检测方法 |
CN114306574B (zh) * | 2021-12-30 | 2023-10-17 | 北京市水产科学研究所(国家淡水渔业工程技术研究中心) | 一种抵抗病原菌感染锦鲤蛋白及其应用 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH09176043A (ja) | 1995-09-23 | 1997-07-08 | Norin Suisansyo Suisanchiyou Youshiyoku Kenkyusho | 魚類用のイリドウイルス感染症ワクチンと診断剤並びにこれ等の製法 |
JPH09285291A (ja) | 1995-11-07 | 1997-11-04 | Ottawa Civic Hospital Loeb Res Inst | 液漬による魚介類のdnaベースワクチン |
JP2002125674A (ja) | 2000-10-19 | 2002-05-08 | Hokkaido | 伝染性造血器壊死症(ihn)ウイルスに対する遺伝子読み枠ワクチン、その製法及び投与法 |
JP2003155254A (ja) * | 2001-09-06 | 2003-05-27 | Meiji Seika Kaisha Ltd | ヒラメラブドウイルス感染魚類用dnaワクチン |
JP2005112726A (ja) | 2003-10-02 | 2005-04-28 | Meiji Seika Kaisha Ltd | ヒラメのウイルス性出血性敗血症に対するdnaワクチン |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL153775A0 (en) * | 2003-01-01 | 2003-07-31 | Yissum Res Dev Co | Immunizing fish against viral infection |
-
2007
- 2007-01-30 WO PCT/JP2007/051498 patent/WO2007119279A1/ja active Application Filing
- 2007-01-30 US US12/296,459 patent/US8052977B2/en not_active Expired - Fee Related
- 2007-01-30 CN CN2007800128639A patent/CN101495636B/zh not_active Expired - Fee Related
- 2007-01-30 EP EP07707716.2A patent/EP2011876B1/en not_active Not-in-force
- 2007-01-30 JP JP2008510736A patent/JP5239023B2/ja active Active
- 2007-04-24 TW TW096114531A patent/TW200842189A/zh unknown
-
2008
- 2008-10-02 IL IL194474A patent/IL194474A0/en unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH09176043A (ja) | 1995-09-23 | 1997-07-08 | Norin Suisansyo Suisanchiyou Youshiyoku Kenkyusho | 魚類用のイリドウイルス感染症ワクチンと診断剤並びにこれ等の製法 |
JPH09285291A (ja) | 1995-11-07 | 1997-11-04 | Ottawa Civic Hospital Loeb Res Inst | 液漬による魚介類のdnaベースワクチン |
JP2002125674A (ja) | 2000-10-19 | 2002-05-08 | Hokkaido | 伝染性造血器壊死症(ihn)ウイルスに対する遺伝子読み枠ワクチン、その製法及び投与法 |
JP2003155254A (ja) * | 2001-09-06 | 2003-05-27 | Meiji Seika Kaisha Ltd | ヒラメラブドウイルス感染魚類用dnaワクチン |
JP2005112726A (ja) | 2003-10-02 | 2005-04-28 | Meiji Seika Kaisha Ltd | ヒラメのウイルス性出血性敗血症に対するdnaワクチン |
Non-Patent Citations (13)
Title |
---|
"Current Protocols in Molecular Biology", 1987, JOHN WILEY & SONS, article "Molecular cloning", pages: 1 - 38 |
"Molecular Cloning: A Laboratory Mannual", 2001, COLD SPRING HARBOR LABORATORY |
"Monoclonal Antibodies and Cancer Therapy", 1985, ALAN R. LISS, INC., pages: 77 - 96 |
BOUDINOT P. ET AL.: "Combined DNA immunization with the glycoprotein gene of viral hemorrhagic septicemia virus and infectious hematopoietic necrosis virus induces double-specific protective immunity and nonspecific response in rainbow trout", VIROLOGY, vol. 249, 1998, pages 297 - 306, XP004445647 * |
DATABASE GENBANK [online] KURITA J. ET AL., XP003018829, Database accession no. (Q75N32) * |
DATABASE GENBANK [online] KURITA J. ET AL., XP003018830, Database accession no. (Q75N31) * |
DATABASE GENBANK [online] KURITA J. ET AL., XP003018831, Database accession no. (Q75N28) * |
DATABASE GENBANK [online] KURITA J. ET AL., XP003018832, Database accession no. (Q75N51) * |
IMMUNOLOGY TODAY, vol. 4, 1983, pages 72 |
MCLAUCHLAN, FISH AND SHELLFISH IMMUNOLOGY, ENGLAND, vol. 15, 2003, pages 39 - 50 |
NATURE, vol. 256, 1975, pages 495 - 497 |
P. BOUDINOT, L, VIROLOGY, (USA, vol. 249, 1998, pages 297 - 306 |
See also references of EP2011876A4 |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010109874A1 (ja) | 2009-03-26 | 2010-09-30 | 国立大学法人東京海洋大学 | コイヘルペスウイルス特異的抗体及びその抗原 |
JP5791047B2 (ja) * | 2009-03-26 | 2015-10-07 | 国立大学法人東京海洋大学 | コイヘルペスウイルス特異的抗体及びその抗原 |
JP2015503914A (ja) * | 2011-12-30 | 2015-02-05 | ユニヴェルシト ド リエージュ | Khvにより引き起こされる疾患の防止のための組換えコイヘルペスウイルス(khv)およびワクチン |
JP2018078903A (ja) * | 2011-12-30 | 2018-05-24 | ゲスバル・ソシエテ・アノニム | Khvにより引き起こされる疾患の防止のための組換えコイヘルペスウイルス(khv)およびワクチン |
Also Published As
Publication number | Publication date |
---|---|
JP5239023B2 (ja) | 2013-07-17 |
CN101495636A (zh) | 2009-07-29 |
EP2011876A1 (en) | 2009-01-07 |
EP2011876B1 (en) | 2014-11-12 |
TW200842189A (en) | 2008-11-01 |
IL194474A0 (en) | 2011-08-01 |
EP2011876A4 (en) | 2010-11-17 |
CN101495636B (zh) | 2012-12-05 |
JPWO2007119279A1 (ja) | 2009-08-27 |
US20090060951A1 (en) | 2009-03-05 |
US8052977B2 (en) | 2011-11-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5239023B2 (ja) | コイヘルペスウイルス(khv)病用dnaワクチン | |
EP2451827B1 (en) | Chimaeric protein | |
WO2022071513A1 (ja) | SARS-CoV-2に対する改良型DNAワクチン | |
KR20230034933A (ko) | Covid-19에 대한 보호를 위한 약독화된 폭스바이러스 벡터 기반 백신 | |
US20210338807A1 (en) | Covid19 vaccines and related methods | |
WO2009082647A2 (en) | Recombinant rift valley fever (rvf) viruses and methods of use | |
AU2020103776A4 (en) | Koi herpesvirus (khv) orf-149-based carbon nanotube supported nucleic acid vaccine and application thereof | |
US20210113684A1 (en) | Vector-based attenuated poxvirus vaccines | |
CN114269939A (zh) | 汉坦病毒抗原组合物 | |
JP4704671B2 (ja) | ヒラメのウイルス性出血性敗血症に対するdnaワクチン | |
US20090162393A1 (en) | Vaccine composition and uses thereof | |
JP6179903B2 (ja) | 海産魚の類結節症に対するdnaワクチン | |
RU2778312C2 (ru) | Вирусные вакцины | |
EP4299728A1 (en) | Recombinant spriviviruses, uses thereof and methods for producing the same | |
CN116457010A (zh) | 新的猫疱疹病毒疫苗 | |
KR20200124713A (ko) | 외인성 펠라인 파라믹소바이러스 유전자를 발현하는 재조합 바이러스 벡터 시스템 및 이로부터 제조된 백신 | |
US20100317567A1 (en) | Diagnosing and protecting horses against papillomavirus |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200780012863.9 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07707716 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008510736 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 194474 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 8417/DELNP/2008 Country of ref document: IN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007707716 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12296459 Country of ref document: US |